Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2019 1
2020 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Computational tools for metabolic engineering.
Copeland WB, Bartley BA, Chandran D, Galdzicki M, Kim KH, Sleight SC, Maranas CD, Sauro HM. Copeland WB, et al. Metab Eng. 2012 May;14(3):270-80. doi: 10.1016/j.ymben.2012.03.001. Metab Eng. 2012. PMID: 22629572 Free PMC article. Review.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig DC, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR. Zeidan AM, et al. Among authors: copeland wb. Blood Adv. 2022 Apr 12;6(7):2219-2229. doi: 10.1182/bloodadvances.2021006138. Blood Adv. 2022. PMID: 34933333 Free PMC article. Clinical Trial.
Increasing gender diversity in the STEM research workforce.
Greider CW, Sheltzer JM, Cantalupo NC, Copeland WB, Dasgupta N, Hopkins N, Jansen JM, Joshua-Tor L, McDowell GS, Metcalf JL, McLaughlin B, Olivarius A, O'Shea EK, Raymond JL, Ruebain D, Steitz JA, Stillman B, Tilghman SM, Valian V, Villa-Komaroff L, Wong JY. Greider CW, et al. Among authors: copeland wb. Science. 2019 Nov 8;366(6466):692-695. doi: 10.1126/science.aaz0649. Science. 2019. PMID: 31699926 No abstract available.
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.
Zeidan AM, Boss I, Beach CL, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G. Zeidan AM, et al. Among authors: copeland wb. Blood Adv. 2022 Apr 12;6(7):2207-2218. doi: 10.1182/bloodadvances.2021005487. Blood Adv. 2022. PMID: 34972214 Free PMC article. Clinical Trial.
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, Reiss DJ, Farmer P, Alapat DV, Singh A, Ashby C, Bauer M, Ren Y, Smith K, Couto SS, van Rhee F, Davies F, Zangari M, Petty N, Orlowski RZ, Dhodapkar MV, Copeland WB, Fox B, Hoering A, Fitch A, Newhall K, Barlogie B, Trotter MWB, Hershberg RM, Walker BA, Dervan AP, Ratushny AV, Morgan GJ. Danziger SA, et al. Among authors: copeland wb. PLoS Med. 2020 Nov 4;17(11):e1003323. doi: 10.1371/journal.pmed.1003323. eCollection 2020 Nov. PLoS Med. 2020. PMID: 33147277 Free PMC article. Clinical Trial.